Price
$803.48+41.52%Social Signal Score
Analyst Ratings
49 analysts52-week range
- Last close
- $803.48
- Off 52w high
- -1.1%
- 200-day average
- $720.14
- vs 200-day
- +11.6%
Revenue
$5.12B+316.99%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Leonard S. Schleifer
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 15,410
- Beta
- 0.24
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 7.81
Financials
Revenue
$5.12B+317.0%Net Income
$1.95B+669.9%EBITDA
$2.42B+552.1%Free Cash Flow
$1.48B+552.2%EPS (diluted)
$18.45+742.5%Shares Outstanding (diluted)
105.60M-8.8%Operating Expenses
$2.49BCash & Debt
$9.30BReturn of Capital
$495.40MRevenue by Segment (annual)
$14.34BDividend per Share
$0.94Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $14.34B | $4.50B | $43.07 |
| 2024 | $14.20B | $4.41B | $40.90 |
| 2023 | $13.12B | $3.95B | $37.05 |
| 2022 | $12.17B | $4.34B | $40.51 |
| 2021 | $16.07B | $8.08B | $76.40 |
| 2020 | $8.50B | $3.51B | $32.65 |
| 2019 | $6.56B | $2.12B | $19.38 |
| 2018 | $6.71B | $2.44B | $21.29 |
| 2017 | $5.87B | $1.20B | $11.27 |
| 2016 | $4.86B | $895.52M | $8.55 |
| 2015 | $4.10B | $636.06M | $6.17 |
| 2014 | $2.82B | $348.07M | $3.36 |
| 2013 | $2.10B | $424.36M | $4.23 |
| 2012 | $1.38B | $750.27M | $7.92 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from REGN's reported EPS growth of 13.9% a year over 13 years.
- EPS in 5 years
- $82.56
- Implied price
- $1,486
- Return from $923.34
- 10.0% a year
To earn 15.0% a year on these assumptions you'd need to buy at $738.85 — -20.0% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| 3.9% | -7.5% | -3.3% | 0.3% | 3.5% | 6.3% |
| 8.9% | -3.0% | 1.4% | 5.2% | 8.5% | 11.4% |
| 13.9% | 1.4% | 6.0% | 10.0% | 13.4% | 16.5% |
| 18.9% | 5.9% | 10.7% | 14.8% | 18.4% | 21.6% |
| 23.9% | 10.3% | 15.4% | 19.6% | 23.4% | 26.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
70+5.88%Social Signal Score
Mentions (81)
- Newszacks.com·2d ago·Positive
Here's Why Regeneron (REGN) is a Strong Momentum Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
View source ↗ - News (RSS)fool·3d ago·Positive
2 Growth Stocks to Buy in November Without Any Hesitation Vertex and Regeneron started 2026 slowly, but blockbuster results and deep pipelines have both stocks climbing again.
View source ↗ - News (Marketaux)manilatimes.net·3d ago·Neutral
Regeneron Highlights New Data Across Malignant and Classical Hematology Programs at American Society of Hematology (ASH) ., Nov. 19, 2026 (GLOBE NEWSWIRE) -- <em[+317 characters]
View source ↗ - Newszacks.com·3d ago·Neutral
REGN Gets FDA Nod for Livsayis in Generalized Myasthenia Gravis Regeneron's Livsayis becomes the first and only siRNA therapy approved by the FDA for generalized myasthenia gravis, offering four subcutaneous doses a year.
View source ↗ - Newsreuters.com·4d ago·Negative
US FDA approves Regeneron's drug for generalized myasthenia gravis US FDA approves Regeneron's drug for generalized myasthenia gravis
View source ↗ - Newsglobenewswire.com·4d ago·Neutral
Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing Approval based on Phase 3 NIMBLE results demonstrating rapid, deep and sustained disease control that is maintained throughout three-month dosing intervals
View source ↗ - Newszacks.com·4d ago·Positive
Regeneron Wins EC Clearance for Libtayo Dosing Flexibility REGN gains EC approval for flexible Libtayo dosing across six cancer indications, potentially improving patient convenience and strengthening its oncology business.
View source ↗ - PodcastAll In·4d ago·Negative
with Regeneron where they found the actual genome responsible chronic liver disease using the delivery, because their researchers there and actually came up with drugs for that. That's confusing. In our decade, if you were to take the claim, we had Dario make any chance that like we cure cancer in the next 10 years. That's a pretty bold statement. It's very hard for me to say, I don't know exactly what's needed. I mean, I think progress will be faster, but for a lot of these things, it also has
View source ↗ - News (RSS)seekingalpha·5d ago·Positive
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
View source ↗ - Newsmarketbeat.com·5d ago·Negative
Regeneron Pharmaceuticals Sees Growth Ahead, Eyes EYLEA HD Syringe Approval Regeneron Pharmaceuticals NASDAQ: REGN expects its three largest growth drivers to continue supporting revenue growth, while planning higher research and development spending and preparing for a specialty drug launch, executives said at the Jefferies Healthcare Conference.
View source ↗ - Newsseekingalpha.com·5d ago·Positive
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies Global Healthcare Conference 2026 Transcript Regeneron Pharmaceuticals, Inc. (REGN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
View source ↗ - Newsfxempire.com·6d ago·Positive
REGN Price Forecast: Rally Faces Resistance After 37% Advance Regeneron shares face growing resistance after a 37% advance, with potential correction targets emerging while the intermediate- and long-term bullish trends remain intact.
View source ↗ - News (RSS)fool·8d ago·Neutral
Regeneron Has $16 Billion in Net Cash and Trades Near 20 Times Earnings. Is It the Cheapest Big Biotech? The stock has climbed more than 40% in one year.
View source ↗ - Newsfool.com·8d ago·Negative
Regeneron Has $16 Billion in Net Cash and Trades Near 20 Times Earnings. Is It the Cheapest Big Biotech? Regeneron sells 16 products, and they have helped revenue climb in recent years. The company's leading products delivered record revenue in the third quarter.
View source ↗ - Newsseekingalpha.com·12d ago·Positive
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Genetic Center and CIDEB siRNA Development for MASH Transcript Regeneron Pharmaceuticals, Inc. (REGN) Discusses Genetic Center and CIDEB siRNA Development for MASH Transcript
View source ↗ - News (RSS)seekingalpha·12d ago·Neutral
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Genetic Center and CIDEB siRNA Development for MASH - Slideshow
View source ↗ - Newsmarketbeat.com·12d ago·Negative
Regeneron Pharmaceuticals Advances Liver Drug After Early Trial Cuts Liver Fat by Up to 80% Regeneron Pharmaceuticals NASDAQ: REGN is advancing its experimental CIDEB therapy into later-stage studies for a form of liver disease after an early trial showed a single dose substantially reduced liver fat, executives said during an investor event.
View source ↗ - Newsglobenewswire.com·14d ago·Negative
CIDEB siRNA Normalizes Liver Fat and Improves Liver Injury Markers in MASLD Patients, as Highlighted at AASLD Single administration of CIDEB siRNA resulted in rapid, deep and durable reductions in liver fat by up to 80% that were sustained through 36 weeks
View source ↗ - Newszacks.com·18d ago·Neutral
Why Regeneron (REGN) Might be Well Poised for a Surge Regeneron (REGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
View source ↗ - Newszacks.com·18d ago·Negative
REGN vs. ILMN: Which Stock Is the Better Value Option? Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Regeneron (REGN) and Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity right now?
View source ↗ - Newsbenzinga.com·20d ago·Positive
These Analysts Raise Their Forecasts On Regeneron Pharmaceuticals After Upbeat Q3 Results Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Friday reported better-than-expected third-quarter 2026 results. Regeneron reported adjusted earnings of $20.07 per share, up 70% year over year and above the analyst consensus estimate of $16.19.
View source ↗ - News (RSS)fool·22d ago·Positive
Regeneron: 3 Key Takeaways for Long-Term Investors An early-stage liver disease therapy cut fat by 70% in just 12 weeks, signaling the genetics engine's potential to fuel growth beyond current blockbusters.
View source ↗ - Newsfool.com·22d ago·Positive
Regeneron: 3 Key Takeaways for Long-Term Investors Dupixent global quarterly net sales grew 35% year over year to $6.5 billion. Total revenue increased 36% year over year to $5.1 billion.
View source ↗ - Newszacks.com·23d ago·Positive
REGN Q3 Earnings Beat on Dupixent Profits & Eylea HD Growth, Stock Up Regeneron's Q3 earnings and revenues beat estimates, fueled by strong Dupixent profits, Eylea HD growth and robust Libtayo demand. Stock up.
View source ↗ - Newsseekingalpha.com·23d ago·Positive
Regeneron Pharmaceuticals, Inc. (REGN) Q3 2026 Earnings Call Transcript Regeneron Pharmaceuticals, Inc. (REGN) Q3 2026 Earnings Call Transcript
View source ↗ - Newsseekingalpha.com·23d ago·Positive
Regeneron Is Just Getting Started Regeneron delivered a standout Q3, with net sales up 36% year-over-year to $5.1 billion, driven mainly by Dupixent's outperformance. Eylea HD and Libtayo posted strong growth, while Eylea 2 mg showed resilience despite biosimilar competition; pipeline updates further reinforced Regeneron's momentum. I now expect 2026 revenues to reach $19 billion, a 33% increase, and non-GAAP EPS growth in the low- to mid-50% range.
View source ↗ - News (RSS)zerohedge·23d ago·Neutral
…third quarter and a fourth-quarter revenue forecast missed expectations. Analysts also debated a plan to limit access to its forums to users with accounts.Regeneron (REGN) climbs 7% after the drugmaker posted revenue and adjusted profit for the third quarter that are ahead of Wall Street’s expectations.Rivian (RIVN) jumps 6% after the maker of electric vehicles reported revenue for the third quarter that beat the average analyst estimate.Roblox (RBLX) slides 18% as the company reported a year-ov…
View source ↗ - Newsmarketbeat.com·23d ago·Neutral
What Regeneron Pharmaceuticals (REGN) Said on Its Q3 Earnings Call Regeneron Pharmaceuticals NASDAQ: REGN reported third-quarter 2026 revenue growth of 36% year over year to $5.1 billion, while non-GAAP diluted earnings per share rose 70% to $20.07. The company attributed the performance to increased Sanofi collaboration revenue and continued growth from DUPIXENT, EYLEA HD and LIBTAYO.
View source ↗ - News247wallst.com·23d ago·Negative
Regeneron Surges 13.55%: Here's What It Means for Your Health Care ETFs Regeneron (NASDAQ:REGN | REGN Price Prediction) shares rose 13.55% in Friday's session, trading at $929.69 as of 9:45 AM ET on Oct 30, 2026. For a biotech worth roughly $94.
View source ↗ - Newszacks.com·23d ago·Neutral
Regeneron (REGN) Reports Q3 Earnings: What Key Metrics Have to Say The headline numbers for Regeneron (REGN) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
View source ↗ - Newszacks.com·23d ago·Positive
Regeneron (REGN) Q3 Earnings and Revenues Beat Estimates Regeneron (REGN) came out with quarterly earnings of $20.07 per share, beating the Zacks Consensus Estimate of $16.08 per share. This compares to earnings of $11.83 per share a year ago.
View source ↗ - Newsglobenewswire.com·23d ago·Neutral
Regeneron Reports Third Quarter 2026 Financial and Operating Results TARRYTOWN, N.Y., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced financial results for the third quarter of 2026 and provided a business update.
View source ↗ - Newsbenzinga.com·23d ago·Neutral
Top Wall Street Forecasters Revamp Regeneron Pharmaceuticals Expectations Ahead Of Q3 Earnings Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) will release its third quarter earnings report before the opening bell on Friday, Oct. 30.
View source ↗ - Newsseekingalpha.com·25d ago·Neutral
Regeneron Earnings Preview: Dupixent Is Booming, But It's Still Overvalued Regeneron Pharmaceuticals is rated Sell at $808, with a fair value of ~$675, implying a 16.4% downside risk. Dupixent's growth is strong, but patent expiration in 2031 and biosimilar risks cap long-term upside reflected in today's price. REGN's EYLEA HD gains are offset by legacy product declines; slowing overall franchise erosion is critical for future cash flow projections.
View source ↗ - Newsglobenewswire.com·27d ago·Negative
Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness Updated agreement expands 2020 procurement agreement with BARDA for Regeneron's first-in-class antibody treatment for Orthoebolavirus zairense , adding value of approximately $270 million
View source ↗ - News (RSS)seekingalpha·31d ago·Neutral
Regeneron: Is The Market Undervaluing Its Growth Potential
View source ↗ - Newsseekingalpha.com·31d ago·Neutral
Regeneron: Is The Market Undervaluing Its Growth Potential At the end of October, Regeneron Pharmaceuticals, Inc. will report its results for Q3. As a reminder, REGN's Q2 revenue rose 18.8% quarter-on-quarter and 16.6% YoY to $4.29 billion, primarily due to the strong performance of Dupixent. On October 12, Regeneron reported positive Phase 3 OPTIMA results, demonstrating sustained Pasatru efficacy in reducing new HO lesions and disease flare-ups in people with FOP.
View source ↗ - Newsfool.com·34d ago·Neutral
Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market Regeneron's leading weight-loss candidate could offer patients an option with fewer side effects. The company has another investigational weight-loss medicine designed to help preserve lean muscle mass.
View source ↗ - Newsfool.com·36d ago·Positive
Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share Regeneron's revenue is growing at a good clip despite declining Eylea sales. Dupixent is the main reason behind recent strong financial results.
View source ↗ - Newsglobenewswire.com·37d ago·Negative
Libtayo® (cemiplimab) Recommended for EU Approval by the CHMP for Updated Dosing Regimen Across All Approved Cancer Types Positive opinion supports reducing Libtayo dosing frequency from every three weeks to every six weeks after first 12 weeks of treatment
View source ↗ - News (Marketaux)gurufocus.com·41d ago·Positive
Regeneron (REGN) Reports Positive 84-Week OPTIMA Trial Results for Pasatru in FOP Patients On October 12, 2026, Regeneron [+345 characters]
View source ↗ - News (RSS)investing·41d ago·Neutral
Regeneron reports sustained efficacy for FOP treatment Pasatru
View source ↗ - Newsbenzinga.com·41d ago·Negative
Regeneron Says Newly Approved Drug Shows Sustained Efficacy In Halting Rogue Bone Growth Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Monday shared encouraging 84-week findings from the Phase 3 OPTIMA trial for its drug Pasatru (garetosmab-grts).
View source ↗ - Newszacks.com·41d ago·Neutral
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report? Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
View source ↗ - Newszacks.com·44d ago·Positive
Why Regeneron (REGN) is a Top Value Stock for the Long-Term Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
View source ↗ - Newsglobenewswire.com·47d ago·Positive
Regeneron Showcases Advances in Care Across Several Cancers and Cancer-associated Complications at ESMO 2026 Late-breaking Phase 3 C-POST data provide longer-term survival outcomes for adjuvant Libtayo ® (cemiplimab) in high-risk cutaneous squamous cell carcinoma (CSCC) after surgery and radiation
View source ↗ - News (RSS)seekingalpha·49d ago·Negative
Regeneron: The Easy Money Has Been Made (Rating Downgrade)
View source ↗ - News (Marketaux)insidermonkey.com·50d ago·Positive
Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets That makes Vertex Pharmaceuticals Incorp[+223 characters]
View source ↗ - Newsbenzinga.com·51d ago·Negative
Regeneron Highlights Promising Ovarian Cancer, Muscle Preservation Trial Data Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Thursday shared clinical trial results for two investigational therapies targeting recurrent ovarian cancer and muscle loss prevention during weight management.
View source ↗ - News (RSS)zerohedge·51d ago·Neutral
Futures Rise, Yields and Oil Drop Ahead Of Key Jobs Report Futures Rise, Yields and Oil Drop Ahead Of Key Jobs Report US futures climbed and bond yields reversed an earlier rise, as a drop in oil prices provides a tailwind in calm trading following a week in which markets were lashed by sharp swings in yields, with the US payrolls report still to come. As of 8:15am ET, S&P 500 futures were up 0.4% after Thursday’s close left the index headed for its worst week since August; Nasdaq 100 contracts
View source ↗ - News (RSS)seekingalpha·52d ago·Positive
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies Transcript
View source ↗ - News (Marketaux)gurufocus.com·52d ago·Neutral
Regeneron Pharmaceuticals (REGN) Reports Promising Ubamatamab Trial Results for Ovarian Cancer On October 01, 2026, Regeneron [+225 characters]
View source ↗ - Newsseekingalpha.com·52d ago·Positive
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies Transcript Regeneron Pharmaceuticals, Inc. (REGN) Discusses Expanded Collaboration on Next-Generation Long-Acting Immunology Antibodies Transcript
View source ↗ - News (RSS)investing·52d ago·Negative
Regeneron reports 73% response rate for ovarian cancer drug trial
View source ↗ - News (RSS)seekingalpha·52d ago·Negative
Sanofi to pay Regeneron up to $8B to expand long-acting drug pipeline
View source ↗ - News (RSS)wsj·52d ago·Negative
Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion The companies will share development and commercialization costs as well as potential future profits from the new drugs, they said.
View source ↗ - News (RSS)investing·52d ago·Neutral
Regeneron, Sanofi expand alliance with $1 billion upfront deal
View source ↗ - Newsreuters.com·53d ago·Negative
Regeneron drug halves muscle loss in combination with Novo's semaglutide in trial An experimental weight-loss drug being developed by Regeneron used in combination with Novo Nordisk's semaglutide reduced the loss of muscle mass by 50% compared with the loss seen with semaglutide alone in a study of patients with obesity, according to data being presented at a medical meeting.
View source ↗ - Newszacks.com·54d ago·Neutral
REGN or ILMN: Which Is the Better Value Stock Right Now? Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Regeneron (REGN) and Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now?
View source ↗ - Newsbenzinga.com·55d ago·Negative
Regeneron Eylea Feels the Pinch as Kodiak Advances Extended Dosing for Eye Drug Regeneron Pharmaceuticals Inc.'s (NASDAQ:REGN) stock is trading lower on Monday, probably in reaction to positive data from Kodiak Sciences Inc.'s (NASDAQ:KOD) data from the Phase 3 DAYBREAK trial for wet age-related macular degeneration (wAMD).
View source ↗ - Newsglobenewswire.com·59d ago·Neutral
Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026 TARRYTOWN, N.Y., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2026 financial and operating results on Friday, October 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
View source ↗ - Newsseekingalpha.com·60d ago·Positive
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
View source ↗ - Newsmarketbeat.com·60d ago·Neutral
Regeneron Highlights EYLEA HD Momentum, Dupixent Growth and Pipeline Catalysts Regeneron Pharmaceuticals NASDAQ: REGN executives highlighted continued growth across key marketed products, a broad late-stage pipeline and an ongoing focus on science-driven business development during a discussion with Bernstein analyst Jeffrey Walch.
View source ↗ - Newsfool.com·61d ago·Positive
Is Regeneron Stock a Bargain Below $800? Regeneron's latest financial results were strong. The company is finding ways to overcome a recent patent cliff.
View source ↗ - News (RSS)fool·68d ago·Neutral
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? Novo Nordisk is bigger and more profitable on paper, but pricing pressure, reduced Medicaid coverage, and intensifying competition are creating headwinds that Regeneron simply does not face right now.
View source ↗ - News (RSS)seekingalpha·68d ago·Positive
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsmarketbeat.com·68d ago·Neutral
Regeneron Highlights Dupixent Growth, Cemdisiran Catalysts and EYLEA HD Momentum Regeneron Pharmaceuticals NASDAQ: REGN outlined growth opportunities for Dupixent, pipeline catalysts for cemdisiran and continued commercial momentum for EYLEA HD during the Morgan Stanley Global Healthcare Conference.
View source ↗ - Newsseekingalpha.com·69d ago·Positive
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Regeneron Pharmaceuticals, Inc. (REGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsmarketbeat.com·71d ago·Neutral
Regeneron Eyes 2026 Catalysts as EYLEA HD and DUPIXENT Drive Growth Regeneron Pharmaceuticals NASDAQ: REGN executives outlined plans for continued growth across its commercial portfolio, upcoming regulatory milestones and pipeline programs during a Wells Fargo investor conference appearance.
View source ↗ - News (Marketaux)seekingalpha.com·74d ago·Positive
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript Regeneron Pharmaceuticals, Inc. (REGN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - News (RSS)yahoo·75d ago·Positive
Evaluating Bullish Potential in Regeneron Pharmaceuticals (REGN) Stock
View source ↗ - News (RSS)fool·79d ago·Positive
Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? They could both outperform the market over the medium term, but one appears to have a clear edge.
View source ↗ - News (RSS)yahoo·87d ago·Negative
Regeneron Pharmaceuticals (REGN) Adjusts Course Amid Mixed Results in Melanoma Drug Trials
View source ↗ - News (RSS)yahoo·88d ago·Neutral
Regeneron Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?
View source ↗ - News (RSS)investing·89d ago·Neutral
Regeneron selects Veeva Vault CRM for global deployment
View source ↗ - Newsseekingalpha.com·89d ago·Positive
Regeneron: Why I Still See Upside After The Rally Regeneron Pharmaceuticals ends August on a high note. The decline in U.S. sales of Eylea following the launch of biosimilars is no longer putting pressure on REGN stock. That's because REGN's Dupixent sales reached €5.15 billion in the second quarter, up 23.6% sequentially.
View source ↗ - Newsglobenewswire.com·95d ago·Neutral
Regeneron Announces Investor Conference Presentations TARRYTOWN, N.Y., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
View source ↗ - Newsreuters.com·95d ago·Negative
US FDA approves Regeneron's rare bone disorder drug The U.S. FDA on Wednesday approved Regeneron's experimental drug for a rare genetic disorder after it significantly reduced abnormal bone formation in certain soft tissues.
View source ↗ - Newsglobenewswire.com·95d ago·Negative
Pasatru™ (garetosmab-grts) First and Only FDA-approved Treatment Demonstrating Reduction in New Heterotopic Ossification (HO) Lesions and Clinician-Assessed Flare-ups in a Placebo-controlled Trial in Adults with Fibrodysplasia Ossificans Progressiva (FOP) FOP is an ultra-rare genetic disorder characterized by rogue bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability
View source ↗ - News (RSS)yahoo·99d ago·Neutral
Is Biohaven (BHVN)’s Latest Regeneron Pharmaceuticals (REGN) Deal a Major Catalyst for its Pipeline?
View source ↗ - Newszacks.com·103d ago·Positive
REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock? Regeneron's Eylea HD and Dupixent strength are fueling growth, while oncology gains and pipeline progress support its outlook.
View source ↗
Earnings
Thu, Jan 28(in 2 months)
Consensus estimate $25.80 per share
Typical surprise +21.6% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Oct 30$20.07 vs $16.51beat
- Thu, Jul 30$14.29 vs $10.16beat
- Wed, Apr 29$9.47 vs $8.91beat
- Fri, Jan 30$11.44 vs $10.74beat
- Tue, Oct 28$11.83 vs $9.65beat
- Fri, Aug 1$12.89 vs $8.43beat
Estimates and results for REGN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by REGN officers and directors.
- Bought
- —
- Sold
- $53.7m
0 trades
69 trades
- Sing George Lsold
- Sing George Lsold
- Sing George Lsold
- Murphy Andrew Jsold
- Murphy Andrew Jsold
- Murphy Andrew Jsold
- Murphy Andrew Jsold
- Murphy Andrew Jsold
31 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Ro Khannahouse · CA17 · disclosed Nov 9, 2026 (33d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 9, 2026 (35d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Aug 12, 2026 (36d later)Buy$1,001 - $15,000
- Alan Armstrongsenate · disclosed Jul 21, 2026 (116d later)Buy$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Jun 9, 2026 (25d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed May 13, 2026 (30d later)Buy$1,001 - $15,000
- Julia Letlowhouse · LA05 · disclosed Mar 13, 2026 (29d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (12d later)Sell$1,001 - $15,000
- Gilbert Cisneroshouse · CA31 · disclosed Dec 15, 2025 (27d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 3, 2025 (4d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 12, 2025 (17d later)Buy$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Jun 10, 2025 (26d later)Buy$1,001 - $15,000
- Byron Donaldshouse · FL19 · disclosed May 26, 2025 (46d later)Sell$1,001 - $15,000
- Byron Donaldshouse · FL19 · disclosed May 26, 2025 (46d later)Sell$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed May 15, 2025 (44d later)Sell$1,001 - $15,000
- Jefferson Shrevehouse · IN06 · disclosed May 9, 2025 (32d later)Sell$15,001 - $50,000
- Robert P. Bresnahanhouse · PA08 · disclosed May 8, 2025 (30d later)Sell$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Mar 28, 2025 (31d later)Sell$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Mar 13, 2025 (29d later)Sell$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Feb 12, 2025 (28d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
